The steady erosion of trust in scientific institutions is a familiar narrative, but a less discussed consequence is the quiet exodus of scientists from those institutions. Recent reporting by KFF Health News reveals a significant and troubling trend: a mass departure of researchers from the National Institutes of Health (NIH) during and after the Trump administration, a departure that extends beyond simple retirements and raises fundamental questions about the future of American biomedical research. This isn’t simply a story of personnel changes; it’s a story about a perceived shift in the purpose of publicly funded science, from a pursuit of knowledge for the public good to a tool for advancing a political agenda. While headlines focus on the number of scientists lost – over 4,400, representing more than 20% of the NIH workforce – the deeper concern lies in who left, why they left, and what capabilities have been irrevocably diminished.
The NIH, the world’s largest public funder of biomedical research, has historically enjoyed bipartisan support, its $48.7 billion fiscal year 2026 budget a testament to its perceived value. Former Senator Roy Blunt, a Missouri Republican and long-time champion of the NIH, expressed his “pleasure” being associated with the agency in 2022. However, this consensus fractured during the latter half of the Trump administration, triggering a wave of departures. Marc Ernstoff, a physician and pioneer in immunotherapy, found his work as a federal scientist “untenable” under the new political climate. Philip Stewart, a researcher at Rocky Mountain Laboratories specializing in tick-borne diseases, retired two years earlier than planned, citing “hurdles” that hampered his ability to conduct effective research. And Alexa Romberg, an addiction prevention scientist focused on tobacco, reported losing substantial research funding when federal grants disappeared, lamenting that tobacco use remains the “No. 1 contributor to early morbidity and mortality that we can prevent.” These aren’t isolated incidents; KFF Health News interviewed six scientists who independently decided to leave their positions years before anticipated due to the perceived tumult.
Source material: CNN.
The data paints a stark picture. While the NIH workforce had been steadily growing – from roughly 17,700 in fiscal year 2019 to 21,100 in 2024 – that growth reversed course under the Trump administration, plummeting to approximately 17,100, the lowest level in at least two decades. It’s crucial to note that the majority of these departures weren’t forced terminations. Roughly 80% retired, resigned, had appointments expire, or transferred to other positions. This suggests a deliberate choice by experienced scientists to disengage, rather than a simple case of layoffs. The administration enacted a hiring freeze and, according to reports, pursued a campaign to remove individuals perceived as disloyal. But beyond these overt actions, scientists describe a more insidious chilling effect: research funds were terminated for topics deemed “off-limits,” access to equipment and supplies was delayed, travel authorizations were denied, and communication with the public was restricted.
The impact of these changes extends beyond stalled projects and delayed discoveries. Daniel Dulebohn, a researcher who left the NIH’s infectious disease and allergy institute, described a “fundamental destruction” that will take “a very, very long time to rebuild.” He and his family have relocated to Mexico, uncertain of his next career move, representing a loss of specialized expertise – in his case, biochemical analysis and operation of rare equipment – that is difficult to replace. This loss isn’t merely academic; as Jennifer Troyer, who left the National Human Genome Research Institute, pointed out, her division lost two-thirds of its staff, leaving insufficient personnel to effectively review research and oversee grants. The agency may still have the funding, but it lacks the capacity to distribute it effectively. This shift, as highlighted by Laura Stark of Vanderbilt University, risks propelling a move towards private-industry research, driven by profit motives rather than public health needs.
The current administration, through Health and Human Services spokesperson Emily Hilliard, defends the changes as a “major reset” focused on “evidence-based research” and streamlining operations. However, this explanation rings hollow to many scientists who witnessed the suppression of research aligned with established scientific consensus. The focus on Lyme disease by HHS Secretary Robert F. Kennedy Jr., while potentially beneficial, doesn’t negate the broader pattern of disruption and the loss of experienced researchers like Philip Stewart, whose work on tracking the spread of Lyme-carrying ticks was hampered by travel delays and bureaucratic obstacles. The question isn’t simply whether the NIH is funding the “right” research, but whether it can function effectively as a neutral arbiter of scientific inquiry, free from political interference.
Looking ahead, the critical question is whether the NIH can attract and retain the talent necessary to fulfill its mission. The exodus of scientists has created a vacuum, and early-career researchers are increasingly looking abroad for opportunities. The long-term consequences of this brain drain are difficult to predict, but the potential for delayed breakthroughs in disease treatment and prevention is significant. We should be watching for a decline in the number of NIH-funded publications in high-impact journals, a decrease in the number of patents originating from NIH research, and a growing reliance on private-sector funding for biomedical research – all indicators that the U.S. is losing its competitive edge in this critical field. The true cost of this disruption won’t be measured in dollars and cents, but in lives potentially lost and opportunities missed.
